David McIntosh Highlights Global Blood Shortages and Fresh vs Stored RBCs
David McIntosh, Founder and Chair at United Plasma Action, reposted from Archil Jaliashvili on LinkedIn:
“This is most interesting work.
However, I repost it with a warning.
What the World is desperately short of right now is a satisfactory supply of red cells – for uses where nothing else will do.
Fresh blood is better than older stored blood – especially for neonates.
We all know that. What’s really fatal is no blood at all.
In about 90% of all cases globally there IS NOT ENOUGH BLOOD.
Therefore, where choices have to be made; where priorities have to be set; the top priority has to be MORE BLOOD PLEASE.
Let’s not get distracted from that fact by anything … not by anything at all, until every blood bank in every hospital in the World has ample stocks.”
Archil Jaliashvili shared in Pharmaceutical & Medical Network: Biotech, Healthcare, Pharma, Devices, Science, Jobs, Events and News public group on LinkedIn:
“What does a blood transfusion actually remedy?
In extreme hemodilution and hemorrhagic shock, focusing on the difference between fresh and stored RBCs.
Core Findings:
Clinically, transfusions are aimed at restoring oxygen-carrying capacity.
– Fresh RBC’ s restore both microvascular perfusion and oxygen capacity;
– Stored RBCs often restore viscosity but less effectively support microvascular perfusion and oxygenation.
Oxygen Affinity (p50)
– Stored RBCs lose 2,3-DPG.
RBC Storage Lesion
Progressive loss of deformability, ATP depletion, morphological changes, microvesicle shedding, increased aggregation, higher free hemoglobin.
These changes reduce FCD, impair O₂ delivery despite normal systemic parameters, and may cause vasoconstriction via NO scavenging.
NO Bioavailability
Hemolysis and free Hb from stored RBCs bind NO → vasoconstriction, reduced perfusion, and potential cardiovascular risk.
NO levels can recover in vivo, but the transient deficiency may be clinically important.
Experimental Conclusions
Fresh RBCs are consistently superior to stored RBCs in animal models — particularly for restoring microvascular perfusion and oxygenation.
The survival benefit may depend as much on restoring FCD as on oxygen capacity.
Clinical transfusion triggers based solely on hemoglobin may overlook perfusion deficits.
Why it matters – Oxygen Bridge: A Bridge to Recovery
BHOC – Biological Hemoglobin Oxygen Carrier.
-No Cross-Matching Required – Ready for immediate use in emergencies.
-High Oxygen-Carrying Efficiency and good perfusion.
-Immediate Restoration of Oxygenation – No need for factors like 2,3-DPG to function.
-Universal Complement to any cases where need efficient oxygenation.
Why it’s key: BHOC is not just a transfusion substitute — it’s an oxygen bridge, ensuring life-saving oxygen delivery in critical moments, from trauma to surgery, when every second counts.
Link to company.

Stay informed with Hemostasis Today.
-
Nov 29, 2025, 18:55Ahmad Thuaimer: Success Story – Advanced Interventional Care for DVT
-
Nov 29, 2025, 17:37Almahdi Ali Explores Ipsilateral Paradoxical Thromboembolism at 22nd European Angiology Days 2025
-
Nov 29, 2025, 17:23Jack Shuang Hou Shares Major Neurology Updates This Week
-
Nov 29, 2025, 16:52Federica Fogacci on Further Strengthening Collaboration Within the Lp(a)CCELERATE Study
-
Nov 29, 2025, 16:42Dr Abdul Mannan on the Echinocyte: Mastering the Diagnostic Duality of Artifact vs. Pathology
-
Nov 29, 2025, 16:42Vikas Dua: Heme Next 1.0 A Conference with a Difference
-
Nov 29, 2025, 16:41Hind Ali: Sources Of Error in Cell Counts
-
Nov 29, 2025, 16:40Maxime Dely: Even on a Break, You Can Give
-
Nov 29, 2025, 16:39Shrinidhi Nathany: HemeNext Brings Science, Technology, and Leadership Together
